CABA Cabaletta Bio Inc
Company Analysis
Latest News
🟢 Cabaletta Bio is trading 5% up today as Nasdaq Composite rises 1.54%
Cabaletta Bio is trading at $3.42, up 5.08%, as broader risk appetite lifts growth and biotechnology stocks. - No newly identified company-specific...
🟢 Cabaletta Bio rises 5.3% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Cabaletta Bio is trading 10.1% up today as biotech stocks rally on positive melanoma-vaccine results
Cabaletta Bio is trading 10.1% up at $3.21, primarily as a biotech-sector rally lifts clinical-stage biotech stocks. - No new company-specific announcement...
🟢 Cabaletta Bio is trading 5% up today after sustained rese-cel Phase 1/2 responses
Cabaletta Bio is trading 5% up at $2.89 after August 17, 2026 reports highlighted encouraging rese-cel Phase 1/2 results, including sustained responses for up...
Cabaletta Bio attracts Bain Capital investment, signaling confidence in drug pipeline
Bain Capital Life Sciences Opportunities III, L.P. disclosed a 9.99% stake in Cabaletta Bio via an amended Schedule 13G filing. The firm held 7,709,188 common...
Cabaletta Bio second quarter 2026 results highlight mid-2027 clinical data and 2H27 BLA submission
Cabaletta Bio reported a second quarter 2026 net loss of $51.0 million, or $0.34 per share, as it continues to advance its late-stage clinical pipeline. The...
Cabaletta Bio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
For the Q2 2026 reporting period, analysts expect Cabaletta Bio to post a loss of $0.37 per share on zero revenue, while the stock currently trades near $2.67...